1. Home
  2. GDEV vs DRUG Comparison

GDEV vs DRUG Comparison

Compare GDEV & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDEV Inc.

GDEV

GDEV Inc.

HOLD

Current Price

$16.45

Market Cap

308.9M

Sector

Technology

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$89.76

Market Cap

364.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDEV
DRUG
Founded
2009
2019
Country
Cyprus
United States
Employees
N/A
N/A
Industry
EDP Services
Pharmaceuticals and Biotechnology
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.9M
364.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GDEV
DRUG
Price
$16.45
$89.76
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$104.00
AVG Volume (30 Days)
2.0K
296.8K
Earning Date
11-24-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
50.98
N/A
EPS
3.08
N/A
Revenue
$412,018,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.89
N/A
P/E Ratio
$5.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.60
$23.18
52 Week High
$42.20
$123.75

Technical Indicators

Market Signals
Indicator
GDEV
DRUG
Relative Strength Index (RSI) 48.78 58.31
Support Level $14.60 $85.65
Resistance Level $15.40 $92.00
Average True Range (ATR) 0.37 9.24
MACD 0.15 -0.08
Stochastic Oscillator 62.66 35.00

Price Performance

Historical Comparison
GDEV
DRUG

About GDEV GDEV Inc.

GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: